BioSpace News Archive

DNA Script announced the broad commercial availability of the fully automated SYNTAX™ DNA printing platform, which consists of the benchtop STX-200 system, latest biochemistry advancements, robust reagent kits, and intuitive software enhancements.

ABVC BioPharma, Inc. today announced that the Vitrargus® Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) on May 15, 2023.

Corium, LLC announced that an analysis of a long-term, 12-month, open-label Phase 3 study of children aged 6-12 using its novel attention-deficit hyperactivity disorder (ADHD) medication AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) showed no clinically significant impact on weight and height growth rate in pediatric patients.

Coherus BioSciences, Inc. today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.

Royal Philips, a global leader in health technology, and Vanderbilt University Medical Center, home to the top-ranked adult and pediatric hospitals in the Southeastern U.S., announced a collaboration that aims to reduce the health system’s carbon footprint while determining a blueprint to guide industry efforts.

GRI Bio, Inc. today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.

Lumos Pharma, Inc., a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency through Phase 2 clinical trials, announced that management will participate in panel discussions at the World Orphan Drug Congress USA 2023, held in Washington, D.C., May 23-25, 2023.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution.

City of Hope announced that one of its researchers will present results from a SWOG Cancer Research Network Phase 3 study comparing nivolumab and brentuximab vedotin in patients with advanced stage classic Hodgkin lymphoma at an ASCO press briefing.

Therapeutic Solutions International (TSOI) announced today its Spin-Off Company, Res Nova Bio, achieved successful delivery of a cancer killing virus to breast cancer, resulting in shrinkage of the tumor without induction of side effects.